Patient: Male, 41-year-old Final Diagnosis: Desmoid tumor of the pancreas Symptoms: Abdominal discomfort Medication: — Clinical Procedure: — Specialty: Surgery Objective: Rare disease Background: Desmoid tumor (DT), also known as aggressive fibromatosis or desmoid-type fibromatosis, is a rare disease. It can occur in anyone at any age, and is more likely to appear in female patients. DTs are sometimes associated with familial adenomatous polyposis and rare syndromes such as Gardner syndrome. Arising from specific cells, fibroblasts, they tend to develop in patients with a history of abdominal surgery and rarely produce metastases. Case Report: We present a case of a 41-year-old man who was referred for abdominal discomfort with no digestive or general symptoms. An abdominal CT scan revealed a mass in the left hypochondrium, corresponding to an intraperitoneal tumor extending to left colon. Based on MRI, we suspected a gastrointestinal stromal tumor. Colonoscopy showed no intraluminal tumor in the colon. A PET-CT scan revealed tumor hypermetabolism and no metastases. The mass was diagnosed as a DT after percutaneous biopsy. Six weeks after diagnosis and as the tumor continued increasing despite pharmacological treatment, the patient underwent surgical pancreatic tail resection with splenectomy and left colonic segmentectomy. Histological examination revealed a 7.047-g DT with severe infiltration of pancreatic parenchyma and transmural colic barrier, with no high-grade differentiation and negative resection margins. The postoperative recovery was uneventful, and we proposed surveil-lance with MRI. Conclusions: The DT was surgically removed and patient remains under MRI surveillance. Other reported management approaches consist of radiotherapy, tyrosine kinase inhibitors, anti-hormonal therapies/non-steroidal anti-inflammatory drugs, chemotherapy, or close surveillance only. This is, to our knowledge, the largest and heaviest DT reported in the modern literature.

completed the induction. ASCT with BEAM was performed in 125 pts (87.4%). Two pts died from septic shock during HDT-SCT. In the subgroup of 139 pts, who were evaluated by CT after induction (and before HDT-SCT) the ORR was 100% (74.8% CR, 25.2% PR). By March 1, 2017, the median follow-up of the living pts was 4 years. At that time, 41 out of 148 (27.8%) analyzed pts experienced disease relapse, and 32 pts (21.6%) had died (8 in

Regorafenib, an oral multikinase inhibitor, was approved in September 2012 by the US Food and Drug Administration for the treatment of patients with metastatic colorectal cancer progressing on standard therapies. Here, we describe the clinical history of a 63-year-old male patient who was treated with regorafenib in the pivotal CORRECT trial. The patient was initially diagnosed in November 2008 with nonmetastatic KRAS-mutated (exon 2, codon 12) rectal cancer. He underwent successful surgery and was treated with 5 cycles of adjuvant chemotherapy. In 2010, lung metastases (KRAS-mutated) were detected and the patient received 6 cycles of FOLFIRI plus bevacizumab. By January 2011, the metastases had progressed. The patient, who was asymptomatic with an Eastern Cooperative Oncology Group performance status of 0, was enrolled onto the CORRECT trial and received best supportive care plus regorafenib (160 mg once daily for 3 weeks of a 4-week cycle) over a period of 2 years, during which time the disease remained stable and the patient remained asymptomatic. Grade 1 anemia and thrombocytopenia were the only treatment-emergent adverse events reported. After receiving 26 cycles of regorafenib, a majority of the lung lesions progressed, and third-line palliative 5-fluorouracil, leucovorin, and oxaliplatin chemotherapy was administered. The patient died in May 2016.

Pour assurer une prise en charge et une qualité de soins optimales, en raison de l'importance de la santé sexuelle pour chaque individu, nous avons évalué la demande concernant la sexualité et la santé sexuelle chez les patients atteints d'un cancer et les besoins de connaissances professionnelles dans ce domaine du personnel soignant. Les résultats ont montré que la sexualité avait une place importante chez les patients et les soignants. De plus, les soignants souhaitent créer un meilleur réseau professionnel, dans le but de rediriger les patients vers des spécialistes, en fonction de leurs besoins spécifiques. Enfin les soignants ont exprimé une volonté de mieux se former en sexologie et en santé sexuelle. The care of the sexuality among oncologic patients A research project within the University hospitals of GenevaCancer affects sexual function, sexual health and relationships as well as mental health and quality of life. Due to the importance of sexual health for each individual and in order to ensure optimal and quality care, we have assessed the demand for sexual health and advise not only among cancer patients but also among professionals in this area and nursing staff. The results showed that sexuality was important both for patients and caregivers. Also we did find out that carers want to create a better professional network with the aim of redirecting patients to specialists according to their specific needs. Carers have also expressed a desire to have relevant training in sexology and sexual health to achieve this.

No abstract